British National Formulary (BNF) 92

September 2026 edition

ISBN: 9780857114990

£89.99 Sterling RRP

The first choice for concise medicines information

Practical and evidence based, British National Formulary (BNF) is the only drug formulary in the world that is both independent, and has rigorous, accredited content creation processes.

Practical and evidence-based, BNF is an integral part of the UK’s healthcare infrastructure and relied on by health professionals who prescribe, dispense, and administer medicines globally.  Containing guidance on best practice in prescribing, as well as legal and ethical considerations, BNF supports safe and effective decision-making at the point of care.

Extensive content updates in the BNF 92 edition include:

New monographs for:

• Imvanex® [smallpox and mpox vaccines] for pre-exposure immunisation and post-exposure prophylaxis against smallpox and mpox infection

• Lyfnua® [gefapixant] for chronic cough

MHRA advice on:

• Chikungunya vaccine (live) (IXCHIQ®): updates to restrictions of use following safety review

• GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases (advice provided in dulaglutide, liraglutide, semaglutide, and tirzepatide drug monographs)

• Improving information supplied with Gabapentinoids (pregabalin/gabapentin), Benzodiazepines and Z-drugs (advice in provided in gabapentin, pregabalin, all benzodiazepines, eszopiclone, zolpidem tartrate, and zopiclone drug monographs)

• Isotretinoin: changes to prescribing guidance and additional risk minimisation measures

• Mesalazine: risk of idiopathic intracranial hypertension

• Semaglutide (Rybelsus®): transition to new formulation and risk of medication error

• Semaglutide (Wegovy®, Ozempic®, and Rybelsus®): risk of non-arteritic anterior ischaemic optic neuropathy (NAION)

Other significant changes include updated guidance on:

• 5α-reductase inhibitors (dutasteride and finasteride): update to monitoring

• Adrenaline/epinephrine: name change to adrenaline

• Antibacterials, use for prophylaxis: updated guidance for endoscopic retrograde cholangiopancreatography, transrectal prostate biopsy, and transurethral resection of prostate

• Cannabis extract: name change to cannabidiol with dronabinol

• Ceftazidime with avibactam: new indication and dose for bacteraemia and update to indication for Gram-negative infections

• Chronic heart failure: updated guidance on management

• COVID-19 vaccines: updated guidance on the Spring 2026 immunisation campaign

• Cyclogest® pessaries [progesterone]: new indication and dose for prevention of preterm birth

• Diarrhoea (acute): updated guidance on the use of antibacterial drugs for acute diarrhoea

• Epilepsy: updated guidance on management

• Givinostat: new important safety information

• Helminth infections: updated guidance for roundworm and hookworm infections

• Hepatitis B vaccine: updated guidance for post-exposure prophylaxis of neonates

• Immunisation schedule: updated guidance for immunisation against respiratory syncytial virus

• Influenza: updated guidance on management

• Migraine: updated guidance on management

• Noradrenaline/norepinephrine: name change to noradrenaline

• Obinutuzumab: new indication and dose for lupus nephritis

• Penicillins and Penicillamine: harm from incorrect recording of a penicillin allergy as a penicillamine allergy [National Patient Safety Alert advice]

• Prednisolone: new indications and doses for adrenalin sufficiency and congenital adrenal hyperplasia

• Respiratory system infections, antibacterial therapy: updated guidance on community-acquired pneumonia and hospital-acquired pneumonia

• Semaglutide (Wegovy®): update to indications and dosing for weight management

• Sepsis: updated guidance on intravenous fluids and vasopressors

• Vaccination, general principle: updated guidance on vaccination in pregnancy

• Vitamins: updated guidance for management of vitamin D deficiency

• Vutrisiran: new indications and dose for treatment of wild-type and hereditary transthyretin amyloidosis inpatients with cardiomyopathy

• Zanamivir: update to indications for prophylaxis and treatment of influenza

BNF is published jointly by BMJ Group and Pharmaceutical Press.